394 related articles for article (PubMed ID: 20030624)
21. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
23. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.
Guo G; Gong K; Ali S; Ali N; Shallwani S; Hatanpaa KJ; Pan E; Mickey B; Burma S; Wang DH; Kesari S; Sarkaria JN; Zhao D; Habib AA
Nat Neurosci; 2017 Aug; 20(8):1074-1084. PubMed ID: 28604685
[TBL] [Abstract][Full Text] [Related]
24. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
25. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.
Zhu H; Acquaviva J; Ramachandran P; Boskovitz A; Woolfenden S; Pfannl R; Bronson RT; Chen JW; Weissleder R; Housman DE; Charest A
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2712-6. PubMed ID: 19196966
[TBL] [Abstract][Full Text] [Related]
27. mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme.
Ramaiah MJ; Kumar KR
Mol Biol Rep; 2021 May; 48(5):4813-4835. PubMed ID: 34132942
[TBL] [Abstract][Full Text] [Related]
28. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
[TBL] [Abstract][Full Text] [Related]
29. Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases.
Qi Q; He K; Yoo MH; Chan CB; Liu X; Zhang Z; Olson JJ; Xiao G; Wang L; Mao H; Fu H; Tao H; Ramalingam SS; Sun SY; Mischel PS; Ye K
J Biol Chem; 2012 Feb; 287(9):6113-27. PubMed ID: 22215664
[TBL] [Abstract][Full Text] [Related]
30. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells.
Panner A; James CD; Berger MS; Pieper RO
Mol Cell Biol; 2005 Oct; 25(20):8809-23. PubMed ID: 16199861
[TBL] [Abstract][Full Text] [Related]
31. EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma.
Yeo AT; Jun HJ; Appleman VA; Zhang P; Varma H; Sarkaria JN; Charest A
Oncogene; 2021 Apr; 40(15):2682-2696. PubMed ID: 33707748
[TBL] [Abstract][Full Text] [Related]
32. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.
Hu X; Pandolfi PP; Li Y; Koutcher JA; Rosenblum M; Holland EC
Neoplasia; 2005 Apr; 7(4):356-68. PubMed ID: 15967113
[TBL] [Abstract][Full Text] [Related]
33. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
[TBL] [Abstract][Full Text] [Related]
34. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo.
Xu W; Bi Y; Kong J; Zhang J; Wang B; Li K; Tian M; Pan X; Shi B; Gu J; Jiang H; Kong X; Li Z
Oncotarget; 2016 Apr; 7(17):24752-65. PubMed ID: 27029073
[TBL] [Abstract][Full Text] [Related]
35. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
36. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
38. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.
Roth P; Weller M
Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii14-9. PubMed ID: 25342600
[TBL] [Abstract][Full Text] [Related]
39. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
Masui K; Tanaka K; Ikegami S; Villa GR; Yang H; Yong WH; Cloughesy TF; Yamagata K; Arai N; Cavenee WK; Mischel PS
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9406-11. PubMed ID: 26170313
[TBL] [Abstract][Full Text] [Related]
40. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
